Grupo de Investigación en Bioquímica y Microbiología GIBIM, Escuela de Química, Universidad Industrial de Santander, A.A. 678, Bucaramanga, Colombia.
Grupo de Investigación en Compuestos Orgánicos de Interés Medicinal CODEIM, Parque Tecnológico Guatiguará, Universidad Industrial de Santander, A. A. 678, Piedecuesta, Colombia.
Chem Biol Interact. 2019 Apr 1;302:164-171. doi: 10.1016/j.cbi.2019.02.002. Epub 2019 Feb 6.
New molecular hybrids were synthesized by combining tetrahydroquinoline (THQ) and isoxazole (ISX) scaffolds, in search for chemical structures with improved pharmacological properties. Our tetrahydroquinoline (THQ) and isoxazole (ISX) hybrids differ in the X and Y substituents: FM53 (X = H; Y= H), FM49 (X = CH; Y= OCH), FM50 (X = Cl; Y= H) and FM48 (X = Cl; Y= OCH). Aiming at exploring their bioactivity in liver cancer cells, in this paper we report the effect of four THQ-ISX hybrids on viability, respiration and oxidative stress in Hep-G2 human hepatoma cells. In addition, we measured the alterations induced by these compounds on oxygen uptake and respiratory chain enzymes in isolated mitochondria. Cell viability assay indicated that these THQ-ISX hybrids displayed antiproliferative activity on Hep-G2 cells. Among these, FM50 (IC = 5.2 ± 1.9 μM) and FM53 (IC = 6.8 ± 0.7 μM) had the highest cytotoxicity. These four hybrids also inhibited the Hep-G2 cells respiration in the uncoupled state, with FM50 decreasing all respiratory states (basal, leak, uncoupled). While only FM49 and FM53 altered the Hep-G2 cells redox function. In terms of mitochondrial bioenergetics, THQ-ISX hybrids decreased the oxygen consumption in state 3 (via complex I and II), and also inhibited NADH oxidase and NADH cytochrome c reductase enzyme activities. In these experiments, the structural homologues FM50 and FM53 had a remarkable inhibitory effect (~50%) with respect to FM49 and FM48. These results show that THQ-ISX hybrids are promising compounds for hepatoma cancer treatment and that the phenyl substituent (Y= H) in the ISX scaffold intensifies both, the cytotoxicity in Hep-G2 cells and, inhibition of electron transport through complex I of the mitochondrial respiratory chain.
新型的分子杂合体是通过将四氢喹啉(THQ)和异恶唑(ISX)结构组合合成的,旨在寻找具有改善药理学性质的化学结构。我们的四氢喹啉(THQ)和异恶唑(ISX)杂合体在 X 和 Y 取代基上有所不同:FM53(X=H;Y=H)、FM49(X=CH;Y=OCH)、FM50(X=Cl;Y=H)和 FM48(X=Cl;Y=OCH)。为了探索它们在肝癌细胞中的生物活性,在本文中我们报告了四种 THQ-ISX 杂合体对 Hep-G2 人肝癌细胞活力、呼吸和氧化应激的影响。此外,我们还测量了这些化合物对分离线粒体中氧摄取和呼吸链酶的影响。细胞活力测定表明,这些 THQ-ISX 杂合体对 Hep-G2 细胞表现出抗增殖活性。其中,FM50(IC=5.2±1.9μM)和 FM53(IC=6.8±0.7μM)具有最高的细胞毒性。这四种杂合体还抑制了 Hep-G2 细胞在去耦联状态下的呼吸,其中 FM50 降低了所有呼吸状态(基础、渗漏、去耦联)。而只有 FM49 和 FM53 改变了 Hep-G2 细胞的氧化还原功能。就线粒体生物能量学而言,THQ-ISX 杂合体降低了状态 3 的耗氧量(通过复合物 I 和 II),并抑制了 NADH 氧化酶和 NADH 细胞色素 c 还原酶的活性。在这些实验中,结构类似物 FM50 和 FM53 对 FM49 和 FM48 具有显著的抑制作用(约 50%)。这些结果表明,THQ-ISX 杂合体是治疗肝癌的有前途的化合物,ISX 支架上的苯基取代基(Y=H)增强了 THQ-ISX 杂合体在 Hep-G2 细胞中的细胞毒性和对线粒体呼吸链复合物 I 的电子传递的抑制作用。